Abel C.

A significant area of research involves head and neck squamous cell carcinoma, encompassing both locally advanced and recurrent or metastatic disease. The investigator participates in trials evaluating PD-1 and PD-L1 inhibitors, including pembrolizumab and nivolumab, in combination with platinum-based chemotherapy or as monotherapy. Research addresses HPV-positive and HPV-negative tumors, exploring differential therapeutic approaches based on viral status.

• Immunotherapy Combinations in HNSCC
• Resected and Locally Advanced Disease
• Recurrent and Metastatic HNSCC

Studies include investigations of laryngeal preservation strategies, comparing induction chemotherapy followed by radiotherapy with concurrent chemoradiotherapy. The research portfolio encompasses trials examining EGFR-targeted therapies and novel agents in patients who have progressed on prior PD-1/PD-L1-based therapy. Work also extends to squamous cell carcinomas of the anal canal and other HPV-associated malignancies.

The investigator engages extensively in research on gastrointestinal malignancies, including gastric and gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, and biliary tract cancer. Studies focus on HER2-positive gastric cancer and combinations involving trastuzumab deruxtecan, as well as immunotherapy approaches in microsatellite instability-high colorectal cancer. Research encompasses both locally advanced unresectable disease and metastatic settings.

• HER2-Positive Gastric and GEJ Adenocarcinoma
• Pancreatic Adenocarcinoma with Novel Combinations
• Advanced Biliary Tract Cancer
• Gastrointestinal Stromal Tumors

Work in gastrointestinal stromal tumors examines resistance mechanisms to tyrosine kinase inhibitors and the role of immunotherapy combinations. The investigator participates in trials addressing neuroendocrine carcinomas of gastroenteropancreatic origin and studies evaluating 5-fluoropyrimidine-based chemotherapy with oxaliplatin. Research also includes investigations of esophageal cancer, both squamous cell and adenocarcinoma subtypes, with emphasis on definitive chemoradiotherapy and immunotherapy maintenance strategies.

This investigator demonstrates involvement in pediatric oncology, focusing on high-risk neuroblastoma, medulloblastoma, ependymoma, and rhabdomyosarcoma. Research encompasses trials evaluating dinutuximab beta in combination with induction chemotherapy regimens and studies of metronomic chemotherapy combined with immunotherapy in relapsed or refractory pediatric solid tumors. Work extends to diffuse intrinsic pontine glioma and other diffuse midline gliomas with H3K28M mutations.

• High-Risk Neuroblastoma
• Central Nervous System Tumors in Children
• Pediatric Sarcomas
• Relapsed and Refractory Pediatric Malignancies

The investigator participates in molecularly targeted trials for pediatric patients, including studies of BRAF-altered tumors, ALK/ROS1/MET-positive malignancies, and FGFR-altered cancers. Research addresses osteosarcoma with poor histological response and Ewing sarcoma, exploring novel combinations and maintenance strategies. Studies also include investigations of hepatoblastoma, retinoblastoma, and rare pediatric renal tumors, emphasizing personalized medicine approaches based on molecular profiling.

The investigator engages in research on genitourinary cancers, with substantial focus on prostate cancer across disease states, including metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and biochemically-relapsed disease. Studies explore androgen receptor pathway inhibitors such as darolutamide and combinations with stereotactic radiotherapy for oligometastatic disease detected by PSMA or choline PET imaging.

• Castration-Resistant Prostate Cancer
• Oligometastatic Prostate Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Research in renal cell carcinoma encompasses both clear cell and non-clear cell histologies, evaluating combinations of VEGF inhibitors and immune checkpoint inhibitors. The investigator participates in trials examining urothelial carcinoma, including studies of antibody-drug conjugates and immunotherapy in both treatment-naïve and previously treated settings. Work also addresses muscle-invasive bladder cancer and explores molecular biomarkers to guide therapeutic selection in advanced genitourinary malignancies.